A research team has identified a molecular mechanism that coordinates the operation of the N-methyl-D-aspartate (NMDA) glutamate receptor, which is key to regulating excitatory synapse function in the ...
NMDA receptors are ionotropic glutamate receptors that mediate excitatory neurotransmission and underpin synaptic plasticity, learning and memory. Their unique voltage-dependent block by magnesium and ...
When it comes to brain proteins, small changes can make a dramatic difference. Researchers studying NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment ...
A new study suggests a potential molecular strategy for treating fragile X syndrome, an inherited neurodevelopmental disorder that causes autism spectrum disorder and intellectual disability. This ...
A new treatment strategy has been proposed to improve core symptoms of autism spectrum disorder (hereafter autism). It is expected to pave the way for developing therapeutics that improve behavioral ...
Treatment-resistant depression presents a substantial clinical challenge, with patients failing to respond adequately to conventional antidepressants. Converging evidence implicates dysregulation of N ...
When it comes to brain proteins, small changes can make a dramatic difference. Researchers studying NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment ...
When it comes to brain proteins, small changes can make a dramatic difference. Researchers studying NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment ...
Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...
Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...
In a recent study published in Nature, researchers developed the MK-801 bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models of metabolic illness by combining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results